Alliance Pharma confirm they are on track with promising growth prospects

The Cambridge Laboratories acquisition has been successfully integrated ahead of schedule, and the group looks forward to the rest of 2010 with confidence.

Sales rose 44 percent from a year earlier, driven by its rheumatology product Deltacortril, and the group is confident of further strong results in 2010.

The company is paying up to £17.8m for privately owned Cambridge Laboratories and expects the deal to be significantly earnings enhancing in the current full year.

The focus on prescription drugs means a stable revenue stream, while the fact that Alliance has a portfolio of 35 of these brands means that it is not overly dependent upon any one product for its overall revenues.

Alliance Pharma PLC (AIM: APH) said it is buying the worldwide rights to the Buccastem and Timodine brands from various subsidiaries of Reckitt Benckiser Group PLC (LSE: RB)  for £7.5 million, of which it will pay £3.7 million ia a vendor share placing.

A chat with Tony Baxter and John Dootson reveals Cyprotex is in rude health - and has some ambitous plans to grow.

Both Nomura Code and Piper Jaffray upbreat after the growing bio-tech firm posted forecast-beating interim results.

Chief Excutive Martyn Coombs believes the company has weathered the worst of the storm in the contract research market, and analyst forecasts see Asterand making up lost ground in the second half.

The company is tying up with the Brazilian arm of the Swiss agri-giant to carry out a field study on its ecologically friendly crop nutrition and protection products.

ReNeuron's Micheal Hunt talks us through a landmark period for the company and the challenges that lie ahead.

Shares in Silence Therapeutics rose 20 per cent as the market continued to digest the news the group could earn as much as $65 million from a collaboration deal with Swiss giant Novartis.

It's been tough since its merger with US-based Intradigm at the start of the year. Investor concerns centre on a potential funding shortfall, but there are reasons to believe boss Philip Haworth and his team will find new sources of finance before the deadline date.

After reporting very good progress for the 2009 full-year in March, the company now announced that revenues in the current year to date are already ahead of board expactations.

Initial trial results for the company's PiNT yield optimiser and CaT calcium absorption technologies shows potato volumes up by more than 25 percent and significant increases in yield.

The group is looking ahead with optimism as human tissue testing is becoming mission critical to the pharmaceutical industry. Asterand is well placed in a market that is growing.